OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate

RecruitingOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Neurotrophic UlcerNeurotrophic KeratitisNeurotrophic Corneal UlcerNeurotrophic Keratoconjunctivitis
Interventions
DRUG

Cenegermin-Bkbj 0.002% Ophthalmic Solution [OXERVATE]

Research subjects will use oxervate in affected eye following approved treatment regimen and have their eye measured with optical coherence tomography and a Cochet-Bonnet esthesiometer at various time points before, during and after treatment.

Trial Locations (1)

11030

RECRUITING

SightMD, Manhasset

All Listed Sponsors
collaborator

Dompé, US, Inc.

UNKNOWN

lead

Sight Medical Doctors PLLC

OTHER

NCT04573647 - OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate | Biotech Hunter | Biotech Hunter